Cumberland launches new Vaprisol product

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the launch of its active promotional campaign to support its new Vaprisol® product. Cumberland will promote Vaprisol across the United States through its hospital sales force. A National Sales Meeting was convened this week to officially launch active promotion and other efforts to support the brand. Cumberland acquired Vaprisol from Astellas Pharma US earlier this year and has been distributing the product since.

Vaprisol® is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with hyponatremia. It is one of two branded prescription products indicated for the treatment of hyponatremia, and is the only intravenous brand available.

Hyponatremia is a common electrolyte disturbance in hospitalized patients, in which sodium ion concentration in blood plasma is lower than normal.  This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. 

Vaprisol offers reliable, defined control with convenient pre-mixed IV dosing for patients with euvolemic and hypervolemic hyponatremia.  This product compliments the activities of the Company's hospital sales force which also promotes Acetadote® and Caldolor®.

"A key component of our growth strategy is to acquire approved brands with market potential that can be unlocked through the active promotional efforts of our sales organization," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We believe Vaprisol reflects our mission to help improve patient care."


Cumberland Pharmaceuticals Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
NYU Langone Health receives "A"s for patient safety from Leapfrog